摘要
前列腺癌是威胁男性健康的重要疾病。但在临床上,不同的治疗手段在后期都会引起不同程度的耐药,其中糖皮质激素的过度表达是引起耐药的重要形式。因此,针对雄激素受体和糖皮质激素受体的联合治疗,逐渐成为了治疗前列腺癌的重要方式。本文总结了糖皮质激素受体引起去势抵抗性前列腺癌耐药的机理,以及用于治疗的双靶点化合物。
Prostate cancer is an important disease that threatens men’s health. However, clinically, different treatment methods will cause different degrees of drug resistance in the later stage, among which the overexpression of glucocorticoids is an important form of drug resistance. Therefore, combination therapy for androgen receptors and glucocorticoid receptors has gradually become an important way to treat prostate cancer. This paper summarises the mechanisms by which glucocorticoid receptors cause drug resistance in depot-resistant prostate cancer and the dual-target compounds used for treatment.
出处
《药物化学》
2023年第1期18-23,共6页
Hans Journal of Medicinal Chemistry
